[1]
Koonin, E.V.; Senkevich, T.G.; Dolja, V.V. The ancient Virus World and evolution of cells. Biol. Direct, 2006, 1(1), 29.
[2]
Breitbart, M.; Rohwer, F. Here a virus, there a virus, everywhere the same virus? Trends Microbiol., 2005, 13(6), 278-284.
[3]
Bayer, M.E.; Blumberg, B.S.; Werner, B. Particles associated with Australia antigen in the sera of patients with leukaemia, Down’s Syndrome and hepatitis. Nature, 1968, 218(5146), 1057-1059.
[4]
Thomas, D.L.; Astemborski, J.; Rai, R.M.; Anania, F.A.; Schaeffer, M.; Galai, N.; Nolt, K.; Nelson, K.E.; Strathdee, S.A.; Johnson, L. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA, 2000, 284(4), 450-456.
[5]
Dallas, H.B.; Zak, A.; Khera, E.; Wen, F. Engineering virus-like particles for antigen and drug delivery. Curr. Protein Pept. Sci., 2018, 19(1), 112-127.
[6]
Teunissen, E.A.; De, M.R.; Mastrobattista, E. Production and biomedical applications of virus-like particles derived from polyomaviruses. J. Control. Release, 2013, 172(1), 305-321.
[7]
Zeltins, A. Construction and characterization of virus-like particles. A review. Mol. Biotechnol., 2013, 53(1), 92-107.
[8]
Grgacic, E.V.; Anderson, D.A. Virus-like particles: Passport to immune recognition. Methods, 2006, 40(1), 60-65.
[9]
Hovlid, M.L. The chemical and genetic engineering of Qbeta viruslike
particles for cell targeting and delivery Dissertations & Theses
– Gradworks,, 2014, 23(2), 100-107.,
[10]
Ott, J.J.; Stevens, G.A.; Groeger, J.; Wiersma, S.T. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine, 2012, 30(12), 2212-2219.
[11]
Ma, L.; Wang, C.; He, Z.; Cheng, B.; Zheng, L.; Huang, K. Peptide-drug conjugate: A novel drug design approach. Curr. Med. Chem., 2017, 24(31), 3373.
[12]
Nakanishi, M.; Eguchi, A.; Akuta, T.; Nagoshi, E.; Fujita, S.; Okabe, J.; Senda, T.; Hasegawa, M. Basic peptides as functional components of non-viral gene transfer vehicles. Curr. Protein Pept. Sci., 2003, 4(2), 141-150.
[13]
Billich, A. HPV vaccine MedImmune/GlaxoSmithKline. Curr. Opin. Investig. Drugs, 2003, 4(2), 210.
[14]
Mulders, P.F.; De, S.M.; Powles, T.; Fizazi, K. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol. Immunother., 2015, 64(6), 655-663.
[15]
Rodríguez-Limas, W.A.; Sekar, K.; Tyo, K.E. Virus-like particles: The future of microbial factories and cell-free systems as platforms for vaccine development. Curr. Opin. Biotechnol., 2013, 24(6), 1089-1093.
[16]
Naskalska, A.; Pyrć, K. Virus like particles as immunogens and universal nanocarriers. Pol. J. Microbiol., 2015, 64(1), 3-13.
[17]
Rawlings, D.J.; Schwartz, M.A.; Jackson, S.W.; Meyer-Bahlburg, A. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat. Rev. Immunol., 2012, 12(4), 282-294.
[18]
Morizono, K.; Chen, I.S. Receptors and tropisms of envelope viruses. Curr. Opin. Virol., 2011, 1(1), 13-18.
[19]
Dan, Y.; Teng, Z.; Sun, S.; Shan, J.; Hu, D.; Yuan, G.; Wei, Y.; Qin, W.; Liu, X.; Hong, Y. Foot-and-mouth disease virus-like particles as integrin-based drug delivery system achieve targeting anti-tumor efficacy. Nanomed. Nanotechnol. Biol. Med, 2016, 13(3), 1061-1070.
[20]
Georgens, C.; Weyermann, J.; Zimmer, W.A. Recombinant virus like particles as drug delivery system. Curr. Pharm. Biotechnol., 2005, 6(1), 49-55.
[21]
Kawano, M.; Matsui, M.; Handa, H. Chapter 15 – Technologies that generate and modify virus-like particles for medical diagnostic and therapy purposes.Design & Development of New Nanocarriers; , 2018, pp. 555-594.
[22]
Zhao, Q.; Chen, W.; Chen, Y.; Zhang, L.; Zhang, J.; Zhang, Z. Self-assembled virus-like particles from rotavirus structural protein VP6 for targeted drug delivery. Bioconjug. Chem., 2011, 22(3), 346.
[23]
Monika, Z.; Agnieszka, P.; Guy, S.; Jean-Pierre, A.; Jadwiga, C.; Bernard, D.; Ewa, S. Adenovirus dodecahedron, as a drug delivery vector. PLoS One, 2009, 4(5), e5569-e5569.
[24]
Chen, H.; Zheng, C.; Zhang, X.; Li, J.; Li, J.; Zheng, L.; Huang, K. Apelin alleviates diabetes-associated endoplasmic reticulum stress in the pancreas of Akita mice. Peptides, 2011, 32(8), 1634-1639.
[25]
Chen, H.; Wang, L.; Wang, W.; Cheng, C.; Zhang, Y.; Zhou, Y.; Wang, C.; Miao, X.; Wang, J.; Wang, C. ELABELA and an ELABELA fragment protect against AKI. J. Am. Soc. Nephrol., 2017, 28(9), 2694-2707.
[26]
Zhou, B.; Ji, K.; Peng, A.; Yang, X.; Huang, K. GLP-1(28-36)amide, a long ignored peptide revisited. Open Biochem. J., 2014, 8(1), 107-111.
[27]
Masarapu, H.; Patel, B.K.; Chariou, P.L.; Hu, H.; Gulati, N.M.; Carpenter, B.L.; Ghiladi, R.A.; Shukla, S.; Steinmetz, N.F. Physalis mottle virus-like particles as nanocarriers for imaging reagents and drugs. Biomacromolecules, 2017, 18(12), 4141-4153.
[28]
Chen, F.; Lu, J.R.; Binder, B.J.; Liu, Y.C.; Hodson, R.E. Application of digital image analysis and flow cytometry to enumerate marine viruses stained with SYBR gold. Appl. Environ. Microbiol., 2001, 67(2), 539-545.
Related Journals
Protein & Peptide Letters
Related Books
Frontiers in Protein and Peptide Sciences
Article Metrics
36
7